ZONALON
Live / Registered — Registered and renewed (as of 21 May 2024)
What this means for you
Registered since 12 Oct 2004. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 12 Oct 2024).
Record
- Serial number
- 78076391
- Registration number
- 2893077
- Mark type
- Word mark
- Filed
- 30 Jul 2001
- Published for opposition
- 20 Jul 2004
- Registered
- 12 Oct 2004
- Next maintenance due
- 12 Oct 2024
- Attorney of record
- Samir R. Patel
Goods and services
- Class 005 — Pharmaceuticals: PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
Owner
- DELCOR ASSET CORPORATION, Canonsburg, PA, US
- FOUGERA PHARMACEUTICALS INC., MELVILLE, NY, US
- Nycomed US Inc., Melville, NY, US
- BRADLEY PHARMACEUTICALS, INC., FAIRFIELD, NJ, US
- BIOGLAN PHARMACEUTICALS COMPANY, Malvern, PA, US
- BIOGLAN PHARMACEUTICALS COMPANY, Malvern, PA, US
- BIOGLAN PHARMACEUTICALS COMPANY, Malvern, PA, US
- Q-BIOGLAN, INC., DURHAM, NC, US
- Bioglan Pharma Plc, Hitchin, Hertfordshire, GB
Prosecution history
- 21 May 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 21 May 2024 — REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
- 21 May 2024 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 15 May 2024 — TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
- 15 May 2024 — POST REGISTRATION ACTION MAILED - SEC. 8 & 9
- 13 May 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 26 Jan 2024 — TEAS SECTION 8 & 9 RECEIVED
- 12 Oct 2023 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 09 Sept 2016 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 09 Sept 2016 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 25 Mar 2015 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
- 04 Mar 2015 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 08 Oct 2014 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 08 Oct 2014 — REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
- 08 Oct 2014 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED